The quassinoid derivative NBT-272 targets both the AKT and ERK signaling pathways in embryonal tumors

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3145-3157

  Castelletti, Deborah ^a   Fiaschetti, Giulio ^a   Dato, Valeria Di ^b   Ziegler, Urs ^c   Kumps, Candy ^d   Preter, Katleen De ^d   Zollo, Massimo ^b   Speleman, Frank ^d   Shalaby, Tarek ^a   Martino, Daniela De ^b   Berg, Thorsten ^e   Eggert, Angelika ^f   Arcaro, Alexandre ^g   Grotzer, Michael A ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NBT 272; PROTEIN KINASE B; QUASSINOID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; EMBRYONAL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G1 PHASE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASMS, GERM CELL AND EMBRYONAL; PHAGOSOMES; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; QUASSINS; S PHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650496926     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0539     Document Type: Article

References (50)

1. Scotting PJ, Walker DA, Perilongo G. Childhood solid tumours: A developmental disorder. Nat Rev Cancer 2005;5:481-8.
2. Grimmer MR, Weiss WA. Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr 2006;18: 634-8.
3. Guessous F, Li Y, Abounader R. Signaling pathways in medulloblastoma. J Cell Physiol 2008;217:577-83.
4. Packer RJ. Childhood brain tumors: Accomplishments and ongoing challenges. J Child Neurol 2008;23:1122-7.
5. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80. (Pubitemid 37009955)
6. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005;17:7-13.
7. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A 1984; 81: 4940-4.
8. Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998;16:3286-94.
9. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001;7:2425-33.
10. Pomeroy SL, Tamayo P, Gaasenbeck M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42.
11. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. c-Myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006;66:673-81.
12. Schmidt EV. The role of c-myc in cellular growth control. Oncogene 1999;18:2988-96.
13. Rosati A, Quaranta E, Ammirante M, Turco MC, Leone A, De Feo V. Quassinoids can induce mitochondrial membrane depolarisation and caspase 3 activation in human cells. Cell Death Differ 2004;11Suppl 2: S216-8.
14. Cuendet M, Pezzuto JM. Antitumor activity of bruceantin: An old drug with new promise. J Nat Prod 2004;67:269-72.
15. Helson L, McChesney J, Bartyzel P. In vitro cytotoxic activity of NBT- 272, a novel quassinoid analog. Geneva: Eur J Cancer 2004;2Suppl; 2004:171.
16. von Bueren AO, Shalaby T, Rajtarova J, et al. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer 2007;7:19.
17. Fukamiya N, Lee KH, Muhammad I, et al. Structure-activity relationships of quassinoids for eukaryotic protein synthesis. Cancer Lett 2005;220:37-48.
18. Lachance PE, Miron M, Raught B, Sonenberg N, Lasko P. Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. Mol Cell Biol 2002;22:1656-63.
19. De Benedetti A, Harris AL. eIF4E expression in tumors: Its possible role in progression of malignancies. Int J Biochem Cell Biol 1999;31:59-72. (Pubitemid 29094790)
20. Bjornsti MA, Houghton PJ. Lost in translation: Dysregulation of capdependent translation and cancer. Cancer Cell 2004;5:519-23.
21. Pyronnet S. Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase MNK1. Biochem Pharmacol 2000;60:1237-43.
22. Sun SY, Rosenberg LM, Wang X, et al. Activation of AKT and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8.
23. Garcia de Veas R, Schweigerer L, Medina MA. Modulation of the proteolytic balance plasminogen activator/plasminogen activator inhibitor by enhanced N-myc oncogene expression or application of genistein. Eur J Cancer 1998;34:1736-40.
24. Kumps C, Van Roy N, Heyrman L, Goossens D, Del-Favero J, Noguera R, et al. Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma. BMC Genomics 2010;11:298.
25. Garzia L, Andolfo I, Cusanelli E, et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 2009;4:e4998.
26. Van Den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:2050-4.
27. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999;98:859-69.
28. Tasdemir E, Galluzzi L, Maiuri MC, et al. Methods for assessing autophagy and autophagic cell death. Methods Mol Biol 2008; 445:29-76.
29. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5: 671-88.
30. Ohsumi Y, Mizushima N. Two ubiquitin-like conjugation systems essential for autophagy. Semin Cell Dev Biol 2004;15:231-6.
31. Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007;282:24131-45.
32. Sears RC. The life cycle of c-myc: From synthesis to degradation. Cell Cycle 2004;3:1133-7.
33. Kim D, Kim SH, Li GC. Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression. Biochem Biophys Res Commun 1999;254:264-8.
34. Kiessling A, Wiesinger R, Sperl B, Berg T. Selective inhibition of c- Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. Chem Med Chem 2007;2:627-30.
35. Wang H, Hammoudeh DI, Follis AV, et al. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 2007;6:2399-408.
36. Song G, Ouyang G, Bao S. The activation of AKT/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59-71.
37. O'Loghlen A, Gonzalez VM, Jurado T, Salinas M, Martin ME. Characterization of the activity of human MAP kinase-interacting kinase MNK1b. Biochim Biophys Acta 2007;1773:1416-27.
38. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005;433:477-80.
39. Ali SM, Sabatini DM. Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J Biol Chem 2005;280:19445-8.
40. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63.
41. Grotzer MA, Castelletti D, Fiaschetti G, Shalaby T, Arcaro A. Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr Cancer Drug Targets 2009;9:176-88.
42. Rouah E, Wilson DR, Armstrong DL, Darlington GJ. N-myc amplification and neuronal differentiation in human primitive neuroectodermal tumors of the central nervous system. Cancer Res 1989;49: 1797-801.
43. Gilbertson RJ, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001;85:705-12.
44. Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 1994;14:5510-22.
45. Guerreiro AS, Fattet S, Fischer B, et al. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res 2008;14:6761-9.
46. Hartmann W, Digon-Sontgerath B, Koch A, et al. Phosphatidylinositol 30-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 2006;12:3019-27.
47. Boller D, Schramm A, Doepfner KT, et al. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 2008;14:1172-81.
48. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of AKT predicts poor outcome in neuroblastoma. Cancer Res 2007;67:735-45.
49. Petricoin EF 3rd, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: AKT/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007;67:3431-40.
50. Benini S, Manara MC, Cerisano V, et al. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects. Int J Cancer 2004;108: 358-66.